Cargando…
Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645289/ http://dx.doi.org/10.1186/2051-1426-3-S2-P145 |
| _version_ | 1782400800212910080 |
|---|---|
| author | Drake, Charles G Quinn, David Dreicer, Robert Antonarakis, Emmanuel Shore, Neal Corman, John Concepcion, Raoul Pieczonka, Christopher Campogan, Dwayne Fan, Li-Qun Chang, Nancy Sheikh, Nadeem Petrylak, Daniel |
| author_facet | Drake, Charles G Quinn, David Dreicer, Robert Antonarakis, Emmanuel Shore, Neal Corman, John Concepcion, Raoul Pieczonka, Christopher Campogan, Dwayne Fan, Li-Qun Chang, Nancy Sheikh, Nadeem Petrylak, Daniel |
| author_sort | Drake, Charles G |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645289 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46452892015-11-20 Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) Drake, Charles G Quinn, David Dreicer, Robert Antonarakis, Emmanuel Shore, Neal Corman, John Concepcion, Raoul Pieczonka, Christopher Campogan, Dwayne Fan, Li-Qun Chang, Nancy Sheikh, Nadeem Petrylak, Daniel J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645289/ http://dx.doi.org/10.1186/2051-1426-3-S2-P145 Text en Copyright © 2015 Drake et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Drake, Charles G Quinn, David Dreicer, Robert Antonarakis, Emmanuel Shore, Neal Corman, John Concepcion, Raoul Pieczonka, Christopher Campogan, Dwayne Fan, Li-Qun Chang, Nancy Sheikh, Nadeem Petrylak, Daniel Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) |
| title | Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) |
| title_full | Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) |
| title_fullStr | Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) |
| title_full_unstemmed | Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) |
| title_short | Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) |
| title_sort | immune response from stride, a randomized, phase ii, open-label study of sipuleucel-t (sip-t) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mcrpc) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645289/ http://dx.doi.org/10.1186/2051-1426-3-S2-P145 |
| work_keys_str_mv | AT drakecharlesg immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT quinndavid immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT dreicerrobert immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT antonarakisemmanuel immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT shoreneal immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT cormanjohn immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT concepcionraoul immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT pieczonkachristopher immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT campogandwayne immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT fanliqun immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT changnancy immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT sheikhnadeem immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc AT petrylakdaniel immuneresponsefromstridearandomizedphaseiiopenlabelstudyofsipuleuceltsiptwithconcurrentvssequentialenzalutamideenzadministrationinmetastaticcastrationresistantprostatecancermcrpc |